2017
Alpha‐lipoic acid (ALA) as a supplementation for weight loss: results from a meta‐analysis of randomized controlled trials
Kucukgoncu S, Zhou E, Lucas K, Tek C. Alpha‐lipoic acid (ALA) as a supplementation for weight loss: results from a meta‐analysis of randomized controlled trials. Obesity Reviews 2017, 18: 594-601. PMID: 28295905, PMCID: PMC5523816, DOI: 10.1111/obr.12528.Peer-Reviewed Original ResearchConceptsAlpha-lipoic acidBody mass indexAlpha-lipoic acid treatmentPlacebo groupWeight lossEffect of ALASignificant short-term weight lossShort-term weight lossModest weight lossPlacebo treatment groupsPlacebo-controlled studyWeight changeAnti-obesity propertiesSystematic literature searchMeta-regression analysisMass indexSignificant morbidityALA doseBMI changeLong-term benefitsWeight managementBMI differencesTreatment groupsMortality rateStudy duration
2011
Individuals with schizophrenia consume more calories while following a similar diet pattern as the general population
Ratliff J, Palmese L, Reutenauer E, Liskov E, Tek C. Individuals with schizophrenia consume more calories while following a similar diet pattern as the general population. The FASEB Journal 2011, 25: 991.1-991.1. DOI: 10.1096/fasebj.25.1_supplement.991.1.Peer-Reviewed Original ResearchBody mass indexNHANES groupMore caloriesSchizophrenia groupPrevalence of obesityCoronary heart diseaseNutrition Examination SurveySchizophrenic individualsLower household incomeMetabolic syndromeWaist circumferenceMass indexExamination SurveyDiet recallHeart diseaseNational HealthAntipsychotic drugsSample patientsAnthropometric measurementsGeneral populationSchizophrenia patientsDiet patternReference groupVulnerable populationsSchizophrenia